From Financial Modeling Prep: 2024-12-23 14:17:00

Brookline Capital Markets analysts have given Exelixis a Buy rating, citing strong commercial presence and growth potential. They predict a $40 per share valuation within 12-18 months. Exelixis is expanding its key therapies and pipeline, with revenue projected to reach $7.1 billion by 2033. Additional indications and new products are key growth drivers, but risks exist in clinical development and market adoption.



Read more at Financial Modeling Prep:: Exelixis Initiated at Buy with Promising Growth Ou…